There are several factors that biopharmaceutical companies should take into account when considering outsourcing primary packaging. This article provides an in-depth look at the benefits of developing packaging strategies as early as possible in the drug development process, how primary packaging should be approached to ensure patient compliance, and different forms of packaging that best protect and improve the stability of a product.
With the rising interest in biopharmaceuticals, drug developers need to quickly understand and evaluate the binding of therapeutic antibodies to Fc receptors.
Continued Process Verification (CPV), Process Analytical Technology (PAT) and Quality by Design (QbD), are driving pharma to improve product and process quality and efficiency.
As the nature of the target molecule becomes increasingly challenging, the need is to move away from the current linear and siloed drug development approach.
The reality is that paper is more of a habit than a requirement. AstraZeneca discovered this when they aimed to introduce ELNs to improve the efficiency of their validated workflows for GMP API manufacture.
Small batches and multiple products in the same plant — these are the market demands to which more and more manufacturers need to adjust. The answer is based on the "Lego principle."
This article takes an in-depth look at how lipid-based drug delivery systems can be used as a bioavailability enhancing technology, as well as the softgel dosage form for their delivery.
A commercial stage medical technology company has developed SMART Softgels featuring a special shell to release quickly while still preventing evaporative loss during and after manufacturing.
Porvair Sciences reports how its P3 microplate can be used to accelerate removal of interfering proteins from serum, plasma or even whole blood samples prior to analysis by Liquid Chromatography / Mass Spectrometry (LC/MS)